CDT Equity Inc. (CDT): Nasdaq/NYSE listing notice — Conduit Pharmaceuticals repays $926k note, receives Nasdaq delisting basis for continued listing deficiencies

CDT Equity Inc.

Paid remaining $926,149 on Senior Note to Nirland Limited on Feb 13, 2025; all assets now free of liens.
On Feb 12, 2025, Nasdaq notified Conduit it did not regain compliance with MVPHS and MVLS requirements; added as delisting bases.
Company presented compliance plan to Nasdaq Hearing Panel on Feb 11; awaiting determination; no assurance of continued listing.
Original Senior Note was $2,650,000 ($500k OID); full satisfaction removes all security interests.

item 1.02 item 8.01 item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CDT Equity Inc. received a nasdaq deficiency notice notice regarding market value (rules 5810(d)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5810(d)(2)

Exact text from the filing

February 12, 2025, Nasdaq informed the Company that the Staff had determined that the Company had not regained compliance with such requirements and as a result, pursuant to Nasdaq Listing Rule 5810(d)(2), these deficiencies now become additional bases for delisting the Company’s securities from the Nasdaq Global Market. The Company has already addressed these concerns before the Nasdaq Hearings Panel, although there can no assurance it will be permitted to implement its plan of compliance and ultimately regain compliance and remain listed on any Nasdaq Market.

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CDT Equity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-007573

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.